Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.

Saved in:
Bibliographic Details
Title: Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.
Authors: Stelljes M; Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany., Middeke JM; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Bug G; Goethe University Frankfurt, University Hospital, Department of Medicine 2, Frankfurt, Germany., Wagner-Drouet EM; Department of Stem Cell Transplantation, University Hospital Mainz, Mainz, Germany., Müller LP; Department of Internal Medicine IV, University Hospital, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany., Schmid C; Department of Hematology and Oncology, Augsburg University Hospital and Medical Faculty, Augsburg, Germany., Krause SW; Department of Internal Medicine 5, Universitätsklinikum Erlangen, Erlangen, Germany., Bethge W; Department of Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tübingen, Germany., Jost E; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, Rheinisch-Westfälische Technische Hochschule Aachen University and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Aachen, Germany., Platzbecker U; Department for Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany., Klein SA; Department of Hematology and Oncology, Universitätsmedizin Mannheim, Mannheim, Germany., Niederland J; Klinik für Hämatologie und Zelltherapie, Helios Klinikum Berlin-Buch, Berlin, Germany., Kaufmann M; Department for Hematology, Oncology and Palliative Medicine, Robert-Bosch-Krankenhaus, Stuttgart, Germany., Schäfer-Eckart K; Klinik für Innere Medizin 5, Onkologie und Hämatologie, Paracelsus Medizinische Privat-Universität, Klinikum Nürnberg, Nuremberg, Germany., Baldauf H; Clinical Trials Unit, DKMS Group, Tübingen und Dresden, Germany., Stölzel F; Division of Stem Cell Transplantation and Cellular Immunotherapy, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany., Trost S; Clinical Trials Unit, DKMS Group, Tübingen und Dresden, Germany., Röllig C; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., von Bonin M; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Egger-Heidrich K; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Kunadt D; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Steffen B; Goethe University Frankfurt, University Hospital, Department of Medicine 2, Frankfurt, Germany., Hauptrock B; Department of Stem Cell Transplantation, University Hospital Mainz, Mainz, Germany., Schliemann C; Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany., Sockel K; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Lang F; Goethe University Frankfurt, University Hospital, Department of Medicine 2, Frankfurt, Germany., Kriege O; Department of Stem Cell Transplantation, University Hospital Mainz, Mainz, Germany., Schaffrath J; Department of Internal Medicine IV, University Hospital, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany., Reicherts C; Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany., Berdel WE; Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany., Serve H; Goethe University Frankfurt, University Hospital, Department of Medicine 2, Frankfurt, Germany., Ehninger G; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Cellex Cell Professionals GmbH, Cologne, Germany., Schmidt AH; Clinical Trials Unit, DKMS Group, Tübingen und Dresden, Germany., Mikesch JH; Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany., Bornhäuser M; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; National Center for Tumor Diseases, Dresden, Germany., Schetelig J; Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Clinical Trials Unit, DKMS Group, Tübingen und Dresden, Germany.
Source: Blood [Blood] 2025 Nov 06; Vol. 146 (19), pp. 2293-2305.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1528-0020
DOI:10.1182/blood.2025028730